G-BA assigns non-quantifiable added benefit to mirdametinib in NF1 plexiform neurofibromas

The 19 March 2026 G-BA resolution on mirdametinib in symptomatic, inoperable NF1 plexiform neurofibromas found a non-quantifiable added benefit at hint-level certainty. Decision text shows how Germany may acknowledge meaningful single-arm efficacy while withholding magnitude quantification when control-based comparative interpretation is structurally constrained.